Cambridge spinout grabs $23M round to launch a new campaign to tackle protein misfolding
A spinout biotech with scientific roots that extend into the University of Cambridge and Lund University has just raised a $23 million A round aimed at a common target in drug development circles: misfolded proteins.
Folding malfunctions are behind a long roster of tough diseases, but have so far resisted efforts at resolving them in a way that can prevent diseases. Wren Therapeutics, based in Cambridge, UK, says the secret to this sauce lies in understanding the “chemical kinetics” behind misfolding.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.